GB2275191A - Use of tolnaftate and tolciclate in treatment of skin disorder - Google Patents
Use of tolnaftate and tolciclate in treatment of skin disorder Download PDFInfo
- Publication number
- GB2275191A GB2275191A GB9302553A GB9302553A GB2275191A GB 2275191 A GB2275191 A GB 2275191A GB 9302553 A GB9302553 A GB 9302553A GB 9302553 A GB9302553 A GB 9302553A GB 2275191 A GB2275191 A GB 2275191A
- Authority
- GB
- United Kingdom
- Prior art keywords
- preparation
- skin
- naphthyl
- psoriasis
- medicaments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 16
- 208000017520 skin disease Diseases 0.000 title claims abstract description 12
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 title abstract description 8
- 229960004880 tolnaftate Drugs 0.000 title abstract description 7
- CANCCLAKQQHLNK-LSDHHAIUSA-N O-[[(1R,8S)-4-tricyclo[6.2.1.02,7]undeca-2(7),3,5-trienyl]] N-methyl-N-(3-methylphenyl)carbamothioate Chemical compound CN(C(=S)Oc1ccc2[C@H]3CC[C@H](C3)c2c1)c1cccc(C)c1 CANCCLAKQQHLNK-LSDHHAIUSA-N 0.000 title abstract description 5
- 229960003916 tolciclate Drugs 0.000 title abstract description 5
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 21
- 239000002674 ointment Substances 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 11
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 9
- 230000000843 anti-fungal effect Effects 0.000 claims abstract description 8
- 229940121375 antifungal agent Drugs 0.000 claims abstract description 8
- 239000006071 cream Substances 0.000 claims abstract description 8
- 230000000699 topical effect Effects 0.000 claims abstract description 7
- 239000003599 detergent Substances 0.000 claims abstract description 3
- 238000010410 dusting Methods 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims abstract description 3
- 239000002453 shampoo Substances 0.000 claims abstract description 3
- 239000000344 soap Substances 0.000 claims abstract description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 claims description 4
- 239000000645 desinfectant Substances 0.000 claims description 4
- 230000001185 psoriatic effect Effects 0.000 claims description 4
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 3
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 3
- 230000001235 sensitizing effect Effects 0.000 claims description 3
- 229960003500 triclosan Drugs 0.000 claims description 3
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
- 235000013871 bee wax Nutrition 0.000 claims description 2
- 239000012166 beeswax Substances 0.000 claims description 2
- 229940092738 beeswax Drugs 0.000 claims description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 2
- 229960003260 chlorhexidine Drugs 0.000 claims description 2
- 229960002242 chlorocresol Drugs 0.000 claims description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 2
- 229940075495 isopropyl palmitate Drugs 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229940068965 polysorbates Drugs 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 210000002268 wool Anatomy 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000003921 oil Substances 0.000 abstract description 3
- 239000000463 material Substances 0.000 description 7
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 6
- 239000003974 emollient agent Substances 0.000 description 6
- 229960002311 dithranol Drugs 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000011280 coal tar Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010017543 Fungal skin infection Diseases 0.000 description 2
- 229940124091 Keratolytic Drugs 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000001530 keratinolytic effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000019028 Epidermal thickening Diseases 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- -1 at about 0.05-5X w/w Chemical compound 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000508 pityriasis versicolor Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
O-2-naphthyl m-N-dimethylthio-carbanilate (tolnaftate) and O-(1,2,3,4-tetrahydro-1,4-methano-6-naphthyl) m-N-dimethylthiocarbanilate (tolciclate) and antifungal analogues thereof are useful in the preparation of (e.g. topical) medicaments for the treatment of attacks of exfoliative or inflammatory skin disorder such as psoriasis. The medicaments can take the form of ointments or creams, or impregnated dressings, bath oils, soap or detergent bars, shampoos, or dusting powders.
Description
PHARMACEUTICAL PREPARATIONS AND THEIR MANUFACTURE AND USE
This invention relates to pharmaceutical preparations for use in the treatment of skin disorders; to their manufacture and use in such treatment; and to the use of certain active ingredients in their manufacture. In particular, the invention relates to the preparation and application of pharmaceutical materials for the treatment of psoriasis.
Psoriasis is a skin disorder characterised by epidermal thickening and scaling.
The prior art includes a number of materials and methods for the treatment of psoriasis. For example, in mild cases, it is known to apply emollients, especially ointments, alone.
Another treatment, known for eczema (dermatitis) as well as for psoriasis, comprises an ointment containing coal tar, often accompanied by salicylic acid. Coal tar is considered to be anti-inflammatory, antipruritic and keratolytic in action, It is known that coal tar preparations are sometimes of limited acceptability to patients, e.g. because of their smell and appearance.
Salicylic acid is also considered to be keratolytic, but often somewhat less active than coal tar: both are thought to act by increasing the rate of loss of surface skin scale. It is known that dizziness, tinnitus and deafness may accompany the use of salicylate.
and allergy may also arise.
Alternative known forms of application of these active ingredients include impregnated dressings, bath oils, and other solutions and dispersions for use in bathing.
A further known treatment for psoriasis comprises 1,8-dihydroxyanthrone (synonym dithranol), often apPlied in the form of an ointment or cream, e.g. at 0.25% w!w. Dithranol has been considered the most potent topical agent for psoriasis. However it can cause unacceptable skin irritation, and it is often regarded as otherwise inconvenient, as it can cause burning if it contacts relatively unaffected skin around the psoriatic lesions, and moreover it stains skin and hair and some fabrics, plastics and enamel, e.g. bathroom ware. For hospital in-patient therapy, dithranol can for example be applied in a paste of zinc oxide, starch and soft paraffin, containing 2% salicylic acid, but has the drawbacks of irritancy and of staining skin and clothing.
Other dithranol-containing ointments are known and intended for 'short-contact' regimes in which they are applied to psoriatic plaques and left in contact for up to one hour before being washed off, thus reducing the effects of burning and staining. Some patients are however intolerant of dithranol.
There remains therefore a continuing need for further materials useful in the treatment of inflammatory or exfoliative skin disorders such as psoriasis.
According to the present invention, a useful treatment of inflammatory or exfoliative skin disorder such as psoriasis is based on a pharmaceutical preparation containing O-2-naphthyl m-N-dimethylthiocarbanilate or O-(1,2,3,4-tetrahydro-1,4-methano-6-naphthyl) m-Ndimethylthiocarbanilate or an antifungal analogue thereof, for example in the form of a preparation for topical application such as an ointment or cream or other emollient base containing an effective amount of the abovementioned active ingredient, e.g. 0.3-3% wlw, e.g.
1% w/w.
O-2-naphthyl m-N-dimethylthiocarbanilate is known as an antifungal pharmaceutical under the generic name tolnaftate, and the analogous substance O-(1,2,3,4-tetrahydro-1,4-methano-6-naphthyl) m-N-dimethylthiocarbanilate is also known as an antifungal pharmaceutical under the generic name tolciclate.
It is also known to apply tolnaftate or tolciclate to the skin in an emollient base, more generally in a cream, lotion, or ointment. But the known indications for such use have previously related to cases of fungal skin infection due to Epidermophyton, Microsporum, Trichophyton and Maiassezia, particularly tinea pedis fungal skin infection, and pityriasis versicolor. Since the known function of this active material is as an anti-infective antifunal agent with a somewhat selective spectrum of action (excluding for example Candida and bacteria), the finding that it is useful for exfoliative or inflammatory skin disorder such as psoriasis is a surprising finding.
Thus the invention includes the use of O-2-naphthyl m-N-dimethylthiocarbanilate or O-(1,2,3,4-tetrahydro-1,4-methano-6-naphthyl) m-Ndimethylthiocarbanilate or an antifungal analogue thereof for the preparation of topical medicaments active against attacks of exfoliative or inflammatory skin disorder such as psoriasis.
It has been found in particular, according to the invention, that tolnaftate ointment or cream can be applied to affected areas of the skin in cases of psoriasis, with beneficial effect. It can be useful also to include a pharmaceutically acceptable disinfectant, particularly a skin disinfectant, or substance with preservative action, in such an ointment or cream, especially in a cream, e.g.
benzalkonium chloride, chlorhexidine, or triclosan, e.g. at about 0.05-5X w/w, e.g. 0.1-0.3%. However, some such materials, e.g.
triclosan, can cause unacceptable skin sensitivity in some patients, so it can be preferable to omit such a material for such cases.
The preparations can be manufactured by conventional pharmaceutical technique. They can usefully be applied twice a day or more often and gently rubbed into affected areas of skin. They can sometimes usefully be covered by dressing if desired.
Particular embodiments of the invention are illustrated nonlimitatively by way of example only, as follows.
EXAMPLE 1
A useful ointment for the treatment of psoriasis can be prepared comprising 1% w/w tolnafate compounded into an emollient base which comprises cetomacrogol emulsifying ointment (emulsifying wax 30%, liauid paraffin 20%, white soft paraffin 50%), using conventional pharmacy technique.
A useful version of this ointment and emollient base, especially for use in cases of notable skin sensitivity, is free of sensitising ingredients. (Ingredients which have sometimes been found to cause sensitivity include beeswax, benzyl alcohol, butylated hydroxyanisole, butylated hydroxytoluene, chlorocresol. EDTA, ethylene diamine, fragrances, hydroxybenzoates, isopropyl palmitate, polysorbates, propylene glycol, sorbic acid, wool fat and related substances.)
EXAMPLE 2
Another useful ointment for the treatment of psoriasis comprises 1% w/w tolnaftate together with 0.1% benzalkonium chloride in an emollient base, commercially available in the form of the preparation marked as Mycil (TM) ointment.
Instructions can be given for the use of such materials (and their analogues including the alternative active ingredients mentioned above) to treat cases of exfoliative or inflammatory skin disorder, particularly psoriasis, substantially as follows:
Such ointments can be applied in sufficient quantity to provide a visible skin covering over areas affected by psoriasis, and worked manually into affected areas of psoriatic skin. This application can be carried out twice a day.
This procedure has been observed to give a noticeable beneficial effect within 24 hours and if continued can clear up psoriatic attacks within about 48 to 72 hours. It can also be useful to apply such ointments and then cover the area of application with a dressing.
An advantage of this treatment is the relatively non-irritant nature of the materials used, and that it can be of particular benefit e.g.
where the patient with psoriasis is intolerant of other known treatments.
According to variants of the invention, tolnaftate or tolciclate or their antifungal analogues can be applied to the skin in cases of exfoliative or inflammatory skin disorder in other presentational forms, such as impregnated dressings, bath oils, soaps and detergent bars, shampoos, or dusting powders. As will be apparent to the skilled reader, the present disclosure extends to modifications and variations including the use of combinations and subcombinations of the features mentioned herein.
Claims (8)
1. Use of O-2-naphthyl m-N-dimethylthio-carbanilate or 0-(1,2,3,4- tetrahydro-1,4-methano-6-naphthyl) m-N-dimethylthiocarbanilate or an antifungal analogue thereof in the preparation of medicaments, e.g.
topical medicaments, for the treatment of attacks of exfoliative or inflammatory skin disorder such as psoriasis.
2. Use of O-2-naphthyl m-N-dimethylthio-carbanilate or 0-(1,2,3,4- tetrahydro-1,4-methano-6-naphthyl) m-N-dimethylthiocarbanilate or an antifungal analogue thereof, together with a pharmaceutically acceptable disinfectant, e.g. a skin disinfectant, or a substance with preservative action, e.g. benzalkonium chloride, chlorhexidine, or triclosan, in the preparation of medicaments, e.g. topical medicaments, for the treatment of attacks of exfoliative or inflammatory skin disorder such as psoriasis.
3. Preparation method according to claim 1 or 2, wherein the medicament is in the form of an ointment or cream.
4. Preparation method according to claim 1 or 2, wherein the medicament is in the form of an impregnated dressing, a bath oil, a soap or detergent bar, a shampoo, or a dusting powder.
5. Preparation according to claim 1, 2, 3 or 4, wherein the resulting medicament is packaged with instructions for applying the medicament to skin that shows exfoliative or inflammatory disorder such as psoriasis.
6. A topical pharmaceutical preparation manufactured according to claim 1 or 2, which is free from potentially sensitising substances that may be unsuitable for psoriatic skin.
7. A topical pharmaceutical preparation manufactured according to claim 1 or 2, which is free from the potentially sensitising substances beeswax, benzyl alcohol, butylated hydroxyanisole, butylated hydroxytoluene, chlorocresol MEDIA, ethylene diamine fragrances, hydroxybenzoates, isopropyl palmitate, polysorbates, propylene glycol, sorbic acid, wool fat and related substances.
8. The invention in all its aspects, substantially as hereinbefore described with reference to any of the features of the foregoing description including the Examples.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9302553A GB2275191B (en) | 1993-02-10 | 1993-02-10 | Use of antifungal compounds in the treatment of skin disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9302553A GB2275191B (en) | 1993-02-10 | 1993-02-10 | Use of antifungal compounds in the treatment of skin disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB9302553D0 GB9302553D0 (en) | 1993-03-24 |
| GB2275191A true GB2275191A (en) | 1994-08-24 |
| GB2275191B GB2275191B (en) | 1996-11-27 |
Family
ID=10730123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB9302553A Expired - Fee Related GB2275191B (en) | 1993-02-10 | 1993-02-10 | Use of antifungal compounds in the treatment of skin disorders |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2275191B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391879B1 (en) * | 1998-11-16 | 2002-05-21 | Astan, Inc. | Therapeutic anti-fungal nail preparation |
| US9408867B2 (en) | 2011-05-11 | 2016-08-09 | Veloce Biopharma, Llc | Antifungal compositions for the treatment of skin and nails |
| US9750683B2 (en) | 2012-02-17 | 2017-09-05 | Veloce Biopharma, Llc | Antifungal compositions for the treatment of skin and nails |
| US10314914B2 (en) | 2015-01-20 | 2019-06-11 | Veloce Biopharma, Llc | Iodophor composition and methods of use |
-
1993
- 1993-02-10 GB GB9302553A patent/GB2275191B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| J.Invest.Dermatol. 100(3) pages 343-346 (1993) * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391879B1 (en) * | 1998-11-16 | 2002-05-21 | Astan, Inc. | Therapeutic anti-fungal nail preparation |
| US9408867B2 (en) | 2011-05-11 | 2016-08-09 | Veloce Biopharma, Llc | Antifungal compositions for the treatment of skin and nails |
| US9750683B2 (en) | 2012-02-17 | 2017-09-05 | Veloce Biopharma, Llc | Antifungal compositions for the treatment of skin and nails |
| US10314914B2 (en) | 2015-01-20 | 2019-06-11 | Veloce Biopharma, Llc | Iodophor composition and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2275191B (en) | 1996-11-27 |
| GB9302553D0 (en) | 1993-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3202237B2 (en) | Desquamation composition containing salicylic acid and a dipolar compound | |
| US12311046B2 (en) | Systems and methods for treating and/or preventing acne | |
| US5425948A (en) | Pharmaceutical compositions for the treatment and prevention of cutaneous and oral mucous membrane inflammations | |
| CN101474140A (en) | Method for delivering substances to the skin and compositions used therein | |
| JP2011126879A (en) | Mild leave-on skin care composition | |
| HUE030308T2 (en) | Formulation for topical wound treatment | |
| CN103796650A (en) | Sandalwood oil and its uses related to skin disorders | |
| KR960000855A (en) | L-carnitine salt and cosmetic composition and pharmaceutical composition for treating skin disease containing same | |
| JP2017509705A (en) | Compositions for the treatment of skin diseases and disorders | |
| KR20020027198A (en) | Method for reduction of inflammation and erythema | |
| US3663716A (en) | Method of treating acne with benzyl alcohol | |
| US4055662A (en) | Antimicrobial composition containing 10-undecensic acid isopropylic ester | |
| EP0666734A1 (en) | Method and composition for prevention and/or treatment of dandruff and seborrhoeic dermatitis | |
| GB2275191A (en) | Use of tolnaftate and tolciclate in treatment of skin disorder | |
| KR20250163412A (en) | Topical formulations and methods of treatment comprising strontium and methylsulfonylmethane (MSM) | |
| AU7733401A (en) | Method for promoting clear skin | |
| GB2216793A (en) | Treatment or prophylaxis of acne, dandruff or related conditions | |
| EP0086228B1 (en) | Use of carbamide peroxide for the manufacture of a medicament for treatment of acne vulgaris | |
| US20060148907A1 (en) | Topical antinflammatory preparations of y-terpinene | |
| KR20190114921A (en) | Ph-sensitive cosmetic composition for improving acne and manufacturing method thereof | |
| JP3675637B2 (en) | Composition for external use | |
| JP3649619B2 (en) | Composition for external use | |
| GB2411833A (en) | Composition for use in the treatment of dry skin conditions | |
| EP1675586A1 (en) | Methods for treating non-microbial inflammatory skin conditions | |
| CA2245254A1 (en) | Glycoside shampoo for treating psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19980210 |
|
| 728V | Application for restoration filed (sect. 28/1977) | ||
| 7281 | Application for restoration withdrawn (sect. 28/1977) |